Moreover, poor treatment response is associated with reduced CD8+ T cells and PD‐L1 expression at the edges of metastatic lesions, along with impaired T cell activation in the liver, which undermines the anti‐tumor immune response [25]. The gene discussed is CD8A; the disease is neoplasm.